Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synthes To Pay $23 Million For Illegal Testing, Marketing Scheme

This article was originally published in The Gray Sheet

Executive Summary

Orthopedic device maker Synthes and its subsidiary Norian will pay a total of $23.2 million in criminal penalties for conducting unauthorized clinical trials of its Norian XR and Norian SRS bone cement products

You may also be interested in...

News Briefs: Boston Sci’s DES Approval; Bard’s Drug-Coated Balloon Submission

Product approvals from Boston Scientific, Bruker and Sorin. Bard completes drug-coated balloon PMA. HHS OIG amends Synthes corporate integrity agreement.

Former Synthes Execs Get Prison Time For Unauthorized Spine Trial

Federal authorities doled out prison time and fines to former executives of spinal fixation firm Synthes, and sent a broader warning to everyone in the industry about the penalties of corporate non-compliance for individuals.

News In Brief

Kensey Nash picks up Norian

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts